{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:36:18Z","timestamp":1792571778949,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,4,12]],"date-time":"2011-04-12T00:00:00Z","timestamp":1302566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s00125-011-2143-3","type":"journal-article","created":{"date-parts":[[2011,4,12]],"date-time":"2011-04-12T03:03:55Z","timestamp":1302577435000},"page":"1756-1765","source":"Crossref","is-referenced-by-count":53,"title":["Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets"],"prefix":"10.1007","volume":"54","author":[{"given":"K.","family":"Aston-Mourney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. L.","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zraika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Udayasankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. L.","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. E.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,12]]},"reference":[{"key":"2143_CR1","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00125-009-1321-z","volume":"52","author":"SE Kahn","year":"2009","unstructured":"Kahn SE, Zraika S, Utzschneider KM, Hull RL (2009) The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 52:1003\u20131012","journal-title":"Diabetologia"},{"issue":"Suppl 3","key":"2143_CR2","doi-asserted-by":"crossref","first-page":"C35","DOI":"10.2337\/diacare.21.3.C35","volume":"21","author":"RC Turner","year":"1998","unstructured":"Turner RC (1998) The U.K. prospective diabetes study. A review. Diabetes Care 21(Suppl 3):C35\u2013C38","journal-title":"Diabetes Care"},{"key":"2143_CR3","first-page":"151","volume":"9","author":"A Clark","year":"1988","unstructured":"Clark A, Wells CA, Buley ID et al (1988) Islet amyloid, increased A-cells, reduced B cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9:151\u2013159","journal-title":"Diabetes Res"},{"key":"2143_CR4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/diabetes.52.2.372","volume":"52","author":"RL Hull","year":"2003","unstructured":"Hull RL, Andrikopoulos S, Verchere CB et al (2003) Increased dietary fat promotes islet amyloid formation and beta-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 52:372\u2013379","journal-title":"Diabetes"},{"key":"2143_CR5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF01219652","volume":"15","author":"P Westermark","year":"1978","unstructured":"Westermark P, Wilander E (1978) The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15:417\u2013421","journal-title":"Diabetologia"},{"key":"2143_CR6","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s00125-008-1255-x","volume":"52","author":"S Zraika","year":"2009","unstructured":"Zraika S, Hull RL, Udayasankar J et al (2009) Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis. Diabetologia 52:626\u2013635","journal-title":"Diabetologia"},{"key":"2143_CR7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bbrc.2006.12.187","volume":"354","author":"S Zraika","year":"2007","unstructured":"Zraika S, Hull RL, Udayasankar J et al (2007) Glucose- and time-dependence of islet amyloid formation in vitro. Biochem Biophys Res Commun 354:234\u2013239","journal-title":"Biochem Biophys Res Commun"},{"key":"2143_CR8","doi-asserted-by":"crossref","first-page":"634","DOI":"10.2337\/diabetes.39.5.634","volume":"39","author":"SE Kahn","year":"1990","unstructured":"Kahn SE, D\u2019Alessio DA, Schwartz MW et al (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 39:634\u2013638","journal-title":"Diabetes"},{"key":"2143_CR9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF00403322","volume":"33","author":"A Clark","year":"1990","unstructured":"Clark A, Saad MF, Nezzer T et al (1990) Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33:285\u2013289","journal-title":"Diabetologia"},{"key":"2143_CR10","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/BF03401591","volume":"1","author":"G Westermark","year":"1995","unstructured":"Westermark G, Arora MB, Fox N et al (1995) Amyloid formation in response to beta cell stress occurs in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide. Mol Med 1:542\u2013553","journal-title":"Mol Med"},{"key":"2143_CR11","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2337\/diabetes.43.12.1457","volume":"43","author":"DA D'Alessio","year":"1994","unstructured":"D\u2019Alessio DA, Verchere CB, Kahn SE et al (1994) Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes 43:1457\u20131461","journal-title":"Diabetes"},{"key":"2143_CR12","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2337\/diabetes.54.7.2235","volume":"54","author":"RL Hull","year":"2005","unstructured":"Hull RL, Shen ZP, Watts MR et al (2005) Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes 54:2235\u20132244","journal-title":"Diabetes"},{"key":"2143_CR13","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s001250051295","volume":"42","author":"DL MacArthur","year":"1999","unstructured":"MacArthur DL, de Koning EJ, Verbeek JS, Morris JF, Clark A (1999) Amyloid fibril formation is progressive and correlates with beta-cell secretion in transgenic mouse isolated islets. Diabetologia 42:1219\u20131227","journal-title":"Diabetologia"},{"key":"2143_CR14","doi-asserted-by":"crossref","first-page":"E882","DOI":"10.1152\/ajpendo.00014.2004","volume":"286","author":"DA D'Alessio","year":"2004","unstructured":"D\u2019Alessio DA, Vahl TP (2004) Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 286:E882\u2013E890","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2143_CR15","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","volume":"28","author":"RA DeFronzo","year":"2005","unstructured":"DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30\u00a0weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092\u20131100","journal-title":"Diabetes Care"},{"key":"2143_CR16","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2337\/dc08-1961","volume":"32","author":"MA Nauck","year":"2009","unstructured":"Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R (2009) Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 32:1237\u20131243","journal-title":"Diabetes Care"},{"key":"2143_CR17","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","volume":"32","author":"B Zinman","year":"2009","unstructured":"Zinman B, Gerich J, Buse JB et al (2009) Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32:1224\u20131230","journal-title":"Diabetes Care"},{"key":"2143_CR18","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1210\/en.2003-0323","volume":"144","author":"L Farilla","year":"2003","unstructured":"Farilla L, Bulotta A, Hirshberg B et al (2003) Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144:5149\u20135158","journal-title":"Endocrinology"},{"key":"2143_CR19","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1210\/en.2002-220405","volume":"143","author":"L Farilla","year":"2002","unstructured":"Farilla L, Hui H, Bertolotto C et al (2002) Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143:4397\u20134408","journal-title":"Endocrinology"},{"key":"2143_CR20","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2337\/diabetes.52.3.751","volume":"52","author":"JG Kim","year":"2003","unstructured":"Kim JG, Baggio LL, Bridon DP et al (2003) Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 52:751\u2013759","journal-title":"Diabetes"},{"key":"2143_CR21","doi-asserted-by":"crossref","first-page":"E745","DOI":"10.1152\/ajpendo.00030.2002","volume":"283","author":"B Rolin","year":"2002","unstructured":"Rolin B, Larsen MO, Gotfredsen CF et al (2002) The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 283:E745\u2013E752","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2143_CR22","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","volume":"48","author":"G Xu","year":"1999","unstructured":"Xu G, Stoffers DA, Habener JF, Bonner-Weir S (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270\u20132276","journal-title":"Diabetes"},{"key":"2143_CR23","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1463-1326.2010.01238.x","volume":"12","author":"R Fan","year":"2010","unstructured":"Fan R, Li X, Gu X, Chan JC, Xu G (2010) Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis. Diabetes Obes Metab 12:815\u2013824","journal-title":"Diabetes Obes Metab"},{"key":"2143_CR24","doi-asserted-by":"crossref","first-page":"421287","DOI":"10.1155\/2008\/421287","volume":"2008","author":"L Khemtemourian","year":"2008","unstructured":"Khemtemourian L, Killian JA, Hoppener JW, Engel MF (2008) Recent insights in islet amyloid polypeptide-induced membrane disruption and its role in beta-cell death in type 2 diabetes mellitus. Exp Diab Res 2008:421287","journal-title":"Exp Diab Res"},{"key":"2143_CR25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1210\/er.2007-0037","volume":"29","author":"L Haataja","year":"2008","unstructured":"Haataja L, Gurlo T, Huang CJ, Butler PC (2008) Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev 29:303\u2013316","journal-title":"Endocr Rev"},{"key":"2143_CR26","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1073\/pnas.87.13.5036","volume":"87","author":"P Westermark","year":"1990","unstructured":"Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 87:5036\u20135040","journal-title":"Proc Natl Acad Sci USA"},{"key":"2143_CR27","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1073\/pnas.93.8.3492","volume":"93","author":"CB Verchere","year":"1996","unstructured":"Verchere CB, D\u2019Alessio DA, Palmiter RD et al (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:3492\u20133496","journal-title":"Proc Natl Acad Sci USA"},{"key":"2143_CR28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00125-008-1185-7","volume":"52","author":"J Udayasankar","year":"2009","unstructured":"Udayasankar J, Kodama K, Hull RL et al (2009) Amyloid formation results in recurrence of hyperglycaemia following transplantation of human IAPP transgenic mouse islets. Diabetologia 52:145\u2013153","journal-title":"Diabetologia"},{"key":"2143_CR29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF00421411","volume":"10","author":"JC Dunbar","year":"1974","unstructured":"Dunbar JC, Foa PP (1974) An inhibitory effect of tolbutamide and glibenclamide (glyburide) on the pancreatic islets of normal animals. Diabetologia 10:27\u201335","journal-title":"Diabetologia"},{"key":"2143_CR30","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1210\/en.131.4.1815","volume":"131","author":"AM Rabuazzo","year":"1992","unstructured":"Rabuazzo AM, Buscema M, Vinci C et al (1992) Glyburide and tolbutamide induce desensitization of insulin release in rat pancreatic islets by different mechanisms. Endocrinology 131:1815\u20131820","journal-title":"Endocrinology"},{"issue":"Suppl 3","key":"2143_CR31","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.2337\/diabetes.53.suppl_3.S205","volume":"53","author":"LL Baggio","year":"2004","unstructured":"Baggio LL, Kim JG, Drucker DJ (2004) Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Diabetes 53(Suppl 3):S205\u2013S214","journal-title":"Diabetes"},{"key":"2143_CR32","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1210\/en.2008-1116","volume":"150","author":"JA Emamaullee","year":"2009","unstructured":"Emamaullee JA, Merani S, Toso C et al (2009) Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. Endocrinology 150:2145\u20132152","journal-title":"Endocrinology"},{"key":"2143_CR33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1749-6632.2010.05802.x","volume":"1212","author":"JA Lavine","year":"2010","unstructured":"Lavine JA, Attie AD (2010) Gastrointestinal hormones and the regulation of beta-cell mass. Ann NY Acad Sci 1212:41\u201358","journal-title":"Ann NY Acad Sci"},{"key":"2143_CR34","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bbrc.2005.03.013","volume":"330","author":"S Bregenholt","year":"2005","unstructured":"Bregenholt S, Moldrup A, Blume N et al (2005) The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 330:577\u2013584","journal-title":"Biochem Biophys Res Commun"},{"key":"2143_CR35","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00125-005-1787-2","volume":"48","author":"L Li","year":"2005","unstructured":"Li L, El-Kholy W, Rhodes CJ, Brubaker PL (2005) Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia 48:1339\u20131349","journal-title":"Diabetologia"},{"key":"2143_CR36","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00125-004-1379-6","volume":"47","author":"J Buteau","year":"2004","unstructured":"Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M (2004) Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47:806\u2013815","journal-title":"Diabetologia"},{"key":"2143_CR37","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.2337\/db09-0685","volume":"58","author":"DA Cunha","year":"2009","unstructured":"Cunha DA, Ladriere L, Ortis F et al (2009) Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes 58:2851\u20132862","journal-title":"Diabetes"},{"key":"2143_CR38","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s00125-009-1329-4","volume":"52","author":"RL Hull","year":"2009","unstructured":"Hull RL, Zraika S, Udayasankar J, Aston-Mourney K, Subramanian SL, Kahn SE (2009) Amyloid formation in human IAPP transgenic mouse islets and pancreas, and human pancreas, is not associated with endoplasmic reticulum stress. Diabetologia 52:1102\u20131111","journal-title":"Diabetologia"},{"key":"2143_CR39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1074\/jbc.M209423200","volume":"278","author":"Y Li","year":"2003","unstructured":"Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ (2003) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471\u2013478","journal-title":"J Biol Chem"},{"key":"2143_CR40","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1210\/en.140.2.778","volume":"140","author":"A Edvell","year":"1999","unstructured":"Edvell A, Lindstrom P (1999) Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +\/?). Endocrinology 140:778\u2013783","journal-title":"Endocrinology"},{"key":"2143_CR41","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1210\/en.2007-0358","volume":"148","author":"NA Sherry","year":"2007","unstructured":"Sherry NA, Chen W, Kushner JA et al (2007) Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 148:5136\u20135144","journal-title":"Endocrinology"},{"key":"2143_CR42","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1172\/JCI119482","volume":"99","author":"Y Wang","year":"1997","unstructured":"Wang Y, Perfetti R, Greig NH et al (1997) Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Investig 99:2883\u20132889","journal-title":"J Clin Investig"},{"key":"2143_CR43","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.2337\/diabetes.52.7.1770","volume":"52","author":"H Kim","year":"2003","unstructured":"Kim H, Haluzik M, Asghar Z et al (2003) Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52:1770\u20131778","journal-title":"Diabetes"},{"key":"2143_CR44","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2337\/diabetes.50.4.785","volume":"50","author":"H Hui","year":"2001","unstructured":"Hui H, Wright C, Perfetti R (2001) Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 50:785\u2013796","journal-title":"Diabetes"},{"key":"2143_CR45","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2337\/dc08-1797","volume":"32","author":"MC Bunck","year":"2009","unstructured":"Bunck MC, Diamant M, Corner A et al (2009) One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32:762\u2013768","journal-title":"Diabetes Care"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-011-2143-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-011-2143-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-011-2143-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T19:21:46Z","timestamp":1560108106000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-011-2143-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,12]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["2143"],"URL":"https:\/\/doi.org\/10.1007\/s00125-011-2143-3","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,12]]}}}